Global Tuberculosis Diagnostic Market Size By Type (Radiographic Method, Diagnostic Laboratory Methods), By Application (Infants, Adults), By Region, And Segment Forecasts, 2023 to 2032

lobal Tuberculosis Diagnostic Market Report Description

The Global Tuberculosis (TB) Diagnostic Market was valued at USD 2.3 billion in 2023 and is projected to reach USD 4.1 billion by 2031, registering a CAGR of 7.5% during 2023–2031. The market growth is driven by the rising prevalence of tuberculosis globally, increasing awareness of early disease detection, and the growing availability of advanced diagnostic technologies.

The World Health Organization (WHO) reports that over 10 million people contract tuberculosis annually, making it one of the top infectious disease killers worldwide. The shift toward rapid molecular diagnostics, improved point-of-care testing, and enhanced public health screening programs are further boosting market demand.

Drivers

✅ Rising Global TB Burden

The high incidence of tuberculosis, especially in low- and middle-income countries, is a primary driver for the market. Global initiatives like WHO’s End TB Strategy are prompting governments to strengthen diagnostic infrastructure.

✅ Technological Advancements in TB Diagnostics

Innovations such as nucleic acid amplification tests (NAAT), GeneXpert MTB/RIF assays, and next-generation sequencing are enabling faster, more accurate detection of TB, including drug-resistant strains.

✅ Government and NGO Funding

Increased funding from international organizations and governments for TB control programs supports the adoption of modern diagnostic tools in both public and private healthcare settings.

Restraints

⛔ High Cost of Advanced TB Tests

Molecular diagnostics and advanced imaging for TB remain expensive, limiting accessibility in resource-constrained settings.

⛔ Limited Laboratory Infrastructure in Developing Regions

Many high-burden countries lack the necessary infrastructure and trained personnel to implement advanced TB diagnostic techniques, slowing down market penetration.

Opportunity

💡 Expansion of Point-of-Care TB Diagnostics

Rapid, portable, and affordable diagnostic devices are creating opportunities for decentralized TB testing, especially in rural and remote areas.

💡 Emerging Markets in Asia-Pacific & Africa

Countries with high TB prevalence, such as India, Indonesia, and South Africa, present untapped growth potential for diagnostic companies, particularly with rising investments in public health.

💡 Integration of AI & Digital Health

Artificial intelligence-powered diagnostic tools and telemedicine platforms are expected to revolutionize TB screening and remote monitoring.

Market by Test Type Insights

Based on test type, molecular diagnostics (NAATs) dominated the market in 2023 due to their ability to detect TB and drug resistance within hours. However, immunodiagnostic tests (interferon-gamma release assays and tuberculin skin tests) still hold significant market share, particularly in screening latent TB infections.

Market by End-Use Insights

By end use, diagnostic laboratories held the largest market share in 2023, driven by the high volume of TB testing performed in centralized labs. Hospitals and clinics are also key end-users, with a growing demand for rapid diagnostic solutions for active TB cases.

Market by Regional Insights

Asia-Pacific dominated the global TB diagnostic market in 2023 due to the region’s high disease burden, with India, China, and Indonesia leading in testing volume.

Africa remains a critical market due to high TB/HIV co-infection rates.

North America & Europe hold steady shares driven by migrant screening programs and efforts to eliminate latent TB infections.

Competitive Scenario

Key players in the Global Tuberculosis Diagnostic Market include Cepheid (Danaher), Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Becton Dickinson & Company, Qiagen, BioMérieux SA, Hain Lifescience, and Oxford Immunotec.

In 2023, Cepheid expanded its GeneXpert MTB/RIF Ultra platform to improve detection sensitivity in high-burden settings.

In 2024, Abbott launched a portable molecular TB test optimized for point-of-care diagnostics.

Roche announced a strategic partnership in 2025 with a leading NGO to expand TB diagnostic access in Africa.

Scope of Work – Global Tuberculosis Diagnostic Market

Key Market Developments

2023: WHO endorsed a new AI-driven digital chest X-ray screening tool for TB detection in low-resource settings.

2024: Qiagen launched an updated version of its QuantiFERON-TB Gold Plus assay for latent TB screening.

2025: Thermo Fisher Scientific introduced a multiplex assay for simultaneous detection of TB and drug resistance markers.

FAQs

1) What is the current market size of the Global Tuberculosis Diagnostic Market?

The market size was USD 2.3 billion in 2023.

2) What is the major growth driver of the Global Tuberculosis Diagnostic Market?

The major growth drivers include the rising global TB burden and the adoption of advanced molecular diagnostics.

3) Which is the largest region during the forecast period in the Global Tuberculosis Diagnostic Market?

Asia-Pacific is expected to remain the largest region due to its high TB prevalence.

4) Which segment accounted for the largest market share in the Global Tuberculosis Diagnostic Market?

Molecular diagnostics (NAATs) accounted for the largest share due to their rapid and accurate detection capabilities.

5) Who are the key market players in the Global Tuberculosis Diagnostic Market?

Key players include Cepheid, Abbott, Roche, Thermo Fisher Scientific, and Becton Dickinson.

Would you like me to also create a visually formatted PDF report version for this market description? Or should I prepare a set of 2–3 competitor benchmarking charts for better visualization?